AMB-CHMINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H29N3O3 |
| Molar mass | 371.5 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AMB-CHMINACA (also known as MA-CHMINACA) is an indazole-based synthetic cannabinoid[1] that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.[2][3][4]
Legal status
AMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[5]
See also
References
- ^ Akamatsu, Shigeki; Yoshida, Masashi (January 2016). "Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray". Journal of Mass Spectrometry. 51 (1): 28–32. doi:10.1002/jms.3722.
- ^ "MA-CHMINACA". Cayman Chemical. Retrieved 21 July 2015.
- ^ "MA-CHMINACA". Southern Association of Forensic Scientists. Retrieved 21 July 2015.
- ^ Samuel D Banister; et al. (July 2016). "The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues". ACS Chemical Neuroscience. doi:10.1021/acschemneuro.6b00137.
{{cite journal}}: Explicit use of et al. in:|author1=(help) - ^ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 21 July 2015.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |